6200 Lookout Road
Boulder, CO 80301
United States
720 647 8519
https://www.enliventherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 46
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Samuel S. Kintz M.B.A. | Co-Founder, CEO, Secretary & Director | 866.41k | N/D | 1986 |
Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder, Chief Scientific Officer & Directors | 632.67k | N/D | 1965 |
Dr. Helen Louise Collins M.D. | Chief Medical Officer | 686.19k | N/D | 1963 |
Mr. Anish Patel Pharm.D. | Co-Founder & COO | N/D | N/D | 1981 |
Mr. Benjamin Hohl | CFO & Head of Corporate Development | 488.5k | N/D | 1990 |
Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development | N/D | N/D | 1977 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
La calificación ISS Governance QuickScore de Enliven Therapeutics, Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 5; Junta: 4; Derechos del accionista: 8; Compensación: 8.